Industry news

Another Success: Pharmaceutical GMP Course!

I was delighted to host and run another of our hugely successful GMP courses to a full house from 16 to 19 May in Manchester. Overall the course feedback was a very reassuring average 4.5/5.

The delivery team were delighted by the many positive comments from delegates both in writing and verbally during the course and are also pleased to receive the constructive criticism for continual improvement. This is a large subject and the feedback ranged from those who wanted more detail to those who thought it was pretty complex with most happily somewhere in between. Although targeted to those in their first 5 years’ experience in the group ranged from those in their first month in the industry to some with up to 15 years’ experience!

The GMP quiz at the end of the course was good fun and had some great teamwork, and although very close there was a clear winning team with some special souvenir pens as prizes. In addition the challenge to come up with new definitions for “GMP” worked well and went with the theme of patient protection.

Several delegates asked at the end of the course what more they could do to continue this training in the years ahead. I would whole heartily recommend specialist training in skill areas to support auditing and self-inspections. (this GMP training is a useful entry to our auditor training courses) Auditing is a great area of focus for the future and is a great learning ground. In addition for those hungry for more detail then I would recommend the Qualified Person and Continual professional development training course whether or not you wish to become a QP, it can lead to Post Graduate qualifications in “Pharmaceutical Quality and GMP” at Certificate , Diploma or MSc level.

A couple of people did comment that they wish the course was run in Amsterdam, well it is! And will run there again on 28 November. We are also planning to run it in Istanbul next year so watch the website for details of this and other courses.

Throughout the course the focus was on protecting the patient and protecting the company and to use knowledge of GMP and the legislation to ensure both these objectives are met

Mike Halliday, NSF-DBA Partner